Tag: pharmaceuticals

  • Finance Friday: 18 February 2011

    Here are recent angel and venture finance transactions for science- and engineering-based companies, as reported by Xconomy and elsewhere. Biomedical/Life Sciences Rosetta Genomics Ltd. in Philadelphia, Pennsylvania. MicroRNA-based molecular diagnostics. $6.0 million, equity. Versartis in Mountain View, California. Protein drugs for endocrine disorders. $21 million in Series B equity financing. Ivivi Health Sciences in San…

  • Contract Awarded for Smallpox Countermeasure Drug Candidate

    Chimerix Inc., a pharmaceutical company in Research Triangle Park, North Carolina, was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to develop the company’s antiviral drug candidate, CMX001 as a medical countermeasure in the event of a smallpox release. The contract has a total potential value of $81 million. CMX001 is…

  • Sanofi-aventis Acquires Genzyme in $20.1B Deal

    Sanofi-aventis, the Paris-based pharmaceutical company, has acquired biotechnology company Genzyme Corporation in Cambridge, Massachusetts for $74.00 per share, or about $20.1 billion. The deal includes other payments to Genzyme shareholders based on net sales and developments involving specific Genzyme drugs. Genzyme is expected to add its treatments for several rare diseases to Sanofi-aventis’s current collection…

  • FDA Grants Orphan Drug Status for ALS Candidate

    BrainStorm Cell Therapeutics Inc. in Petach Tikvah, Israel says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s NurOwn adult stem cell product candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. ALS is a progressive neurodegenerative disease of nerve cells in the…

  • Pharma Companies Partner on Dengue Drugs

    Medivir AB, a specialty pharmaceutical company in Huddinge, Sweden, will collaborate with Janssen Pharmaceutica N.V. in Beerse, Belgium on drugs for the prevention and treatment of dengue virus infection. Both companies plan to use their expertise in protease inhibitors for this partnership. According to the World Health Organization, dengue is the most common mosquito-borne viral…

  • Dengue Fever Vaccine Promotion Initiative Unveiled

    The International Vaccine Institute announced the launch of the Dengue Vaccine Initiative (DVI), a joint project that aims to reduce the economic and infrastructure barriers to the use of a dengue vaccine. Participants include the Sabin Vaccine Institute, Johns Hopkins University, and World Health Organization, with funding from a $6.9 million grant from the Bill…

  • Research Suggests Strategy for Stockpiled Avian Flu Vaccine

    A new study suggests that current stockpiles of avian influenza (H5N1) vaccine can be part of an effective strategy to protect against a new pandemic, even though the vaccine was developed for an earlier strain of the virus. The researchers from three universities, the Mayo Clinic in Minnesota, Group Health Research Institute in Washington state,…

  • New Techniques Developed to Bind Peptides, Proteins

    Research chemists at University at Buffalo in New York have devised two new ways of binding peptides to helix-shaped proteins, making the peptides more resistant to enzymes and more valuable in therapies. One of those binding techniques, called photoclick stapling, is described in a paper published online last month in the journal Bioorganic and Medicinal…

  • Drug Reduces Stroke Victim Brain Inflammation, Disability

    Researchers at the Institute for Neurological Research in Los Angeles, California report reductions in brain inflammation and neurological disabilities in stroke victims after administration of the drug etanercept. The proof-of-concept research was published in the 1 February 2011 issue of the journal CNS Drugs (paid subscription requried). Etanercept is a drug that blocks tumor necrosis…

  • Pfizer Slashes R&D Funding, Closes U.K. Research Site

    Pfizer Inc. in New York said today it plans to cut its research and development spending to keep R&D costs in line with lower expected revenues in 2012. The reductions, which Pfizer calls “significant,” include closing its research facility in Sandwich, U.K. and consolidating research operations in the northeast U.S. The company has lowered its…